<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04593355</url>
  </required_header>
  <id_info>
    <org_study_id>20110101</org_study_id>
    <nct_id>NCT04593355</nct_id>
  </id_info>
  <brief_title>HCV Epidemiological Survey in China Rural Area</brief_title>
  <acronym>HCVES</acronym>
  <official_title>HCV Epidemiological Survey of Chinese in Northeast Rural Area Which Have Injection History</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Hospital of Jilin University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the morbidity of hepatitis C with Chinese&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis C virus (HCV) infection rate in China is about 3%, which means about 30 million&#xD;
      patients. More importantly, many of those patients with chronic hepatitis C eventually&#xD;
      develop cirrhosis and hepatocellular carcinoma(HCC).Our survey found the rate of hepatitis c&#xD;
      infection in northeastern China without intervention is 34.3%, due to the abuse of caffeine&#xD;
      sodium benzoate. This population has the similar mode of transmission, which is a fine study&#xD;
      of the natural outcome hepatitis C. We plan to carry out epidemiological studies for this&#xD;
      population, review of the influencing factors of the disease, and analyze the host factors&#xD;
      that can effect the prognosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Blood Anti-HCV</measure>
    <time_frame>Baseline</time_frame>
    <description>Co-infection status are analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT) and Aspartate transaminase (AST)</measure>
    <time_frame>Baseline</time_frame>
    <description>ALT AST are assayed to detect the hepatic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis stage</measure>
    <time_frame>Baseline</time_frame>
    <description>Fibrosis is analyzed with Fibroscan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regular blood test</measure>
    <time_frame>Baseline</time_frame>
    <description>The distribution and absolute count of the different types of blood cells are assayed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood HCV RNA Copies</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood HCV RNA copies were assayed with Roche - COBAS® AmpliPrep/COBAS® TaqMan® HCV Test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV genotype</measure>
    <time_frame>Baseline</time_frame>
    <description>HCV NS5A is cloned into T vector and sequenced for evolutionary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug abuse history</measure>
    <time_frame>Baseline</time_frame>
    <description>Patients will be asked about their drug usage history.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alcohol ,smoking condition</measure>
    <time_frame>Baseline</time_frame>
    <description>Patients are asked whether they take alcohol or smoke cigarettes during the therapy period.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">6068</enrollment>
  <condition>Hepatitis</condition>
  <arm_group>
    <arm_group_label>HCV</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood serum,Peripheral blood mononuclear cells (PBMC),Urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients are from the northeast of China. Most of the patients have been infected by the&#xD;
        hepatitis c virus due to the drug abuse. Many of them share the same syringe for drug&#xD;
        intravenous injection. However, HIV infection has been rarely detected.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged from 20 to 65&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has history of decompensated liver diseases&#xD;
&#xD;
          -  Has been treated with other anti-virus drugs,or anti-tumor drugs,immuno-suppression&#xD;
             drugs&#xD;
&#xD;
          -  Has a history of autoimmune hepatitis&#xD;
&#xD;
          -  History of a severe seizure disorder or current anticonvulsant use&#xD;
&#xD;
          -  History or other evidence of a medical condition associated with chronic liver disease&#xD;
             other than HCV which would make the patient, in the opinion of the investigator,&#xD;
             unsuitable for the study (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver&#xD;
             disease, alcoholic liver disease, toxin exposures)&#xD;
&#xD;
          -  Patients with documented or presumed coronary artery disease or cerebrovascular&#xD;
             disease should not be enrolled if, in the judgment of the investigator, an acute&#xD;
             decrease in hemoglobin by up to 4g/dL (as may be seen with ribavirin therapy) would&#xD;
             not be well-tolerated&#xD;
&#xD;
          -  History of thyroid disease poorly controlled on prescribed medications, elevated&#xD;
             thyroid stimulating hormone (TSH) concentrations with elevation of antibodies to&#xD;
             thyroid peroxidase and any clinical manifestations of thyroid disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junqi Niu, PhD/MD</last_name>
    <role>Study Chair</role>
    <affiliation>The First Hospital of Jilin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Hospital Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.jdyy.cn/</url>
    <description>Hospital's homepage</description>
  </link>
  <link>
    <url>http://www.shanghaipasteur.cas.cn/</url>
    <description>Cooperator's homepage</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Hospital of Jilin University</investigator_affiliation>
    <investigator_full_name>Junqi Niu</investigator_full_name>
    <investigator_title>Vice-President of First Hospital of Jilin University</investigator_title>
  </responsible_party>
  <keyword>Predict</keyword>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Metabolomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

